Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94403Research ArticleHigh doses of trospium chloride in patients with overactive bladderdue to neurologic disease. The multicenter observational program RESOURCEKrivoborodovG. Gdr.krivoborodov@yandex.ruTurE. Iamadeymozart@yandex.ruEfremovN. S-ShkolnikovM. E-N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation151220151712646728122021Copyright © 2015, Consilium Medicum2015In a multicenter observational programs RESOURCE were included 324 (181 female and 143 male) patients with overactive bladder due to neurologic disease. The average age of patients was 59.4±0.7 years (23 to 94). The purpose of research was to evaluate the efficacy and safety of high doses of trospium chloride in patients with overactive bladder due to neurologic disease. According to the study it was found that 11 patients stopped treatment because of severe side effects, 8 preferred dose of trospium chloride 15 mg/day, 25 - 30 mg/day, 155 - 45 mg/day, 115 - 60 mg/day, 7 - 75 mg/day, 2 - 90 mg/day and 1 - 120 mg/day. There was no direct proportional relationship between increasing doses of trospium chloride, and improving symptoms of urgent and frequent urination. Thus, an individual approach in dose selection trospium chloride in patients with neurogenic overactive bladder can be quite effective and safe measure to achieve optimal clinical outcome with a good safety profile.overactive bladderurge urinary incontinenceneurological diseasestrospium chlorideгиперактивный мочевой пузырьургентное недержание мочиневрологические заболеваниятроспия хлорид[Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.][Milsom I, Abrams P, Cardozo L et al. How widespread are the symptomes of an overactive bladder and how are they managed? A population - based prevalence study. Br J Urol Int 2001; 87: 760-6.][Reeves Р, Irwin D, Kelleher C et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006; 50 (5): 1050-7.][Stohrer M et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; 56 (1): 81-8.][Andersson K.E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011.][Madhuvrata P et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta - analysis. Eur Urol 2012; 62 (5): 816-30.][Menarini M et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44 (12): 623-32.][Isik A.T et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13 (8): 672-6.]